PROTOCOL FOR ASSESSMENT OF GEMCITABINE AND PACLITAXEL FOR METASTIC UROTHELIAL

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。主要目的是评估入组70岁或以上晚期尿路上皮癌患者参加II期研究的可行性。将评估疗效、毒性和耐受性。将评价共病、抑郁和功能状态的自我报告测量。将评估药物紫杉醇和吉西他滨在该年龄组和60岁以下患者中的临床药理学。60岁以下的患者将与文献中报告的患者进行比较。将探讨探索遗传多态性的可行性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to assess the feasiblity of enrolling patients aged 70 or older with advanced urothelial cancer to a Ph II study. The efficacy, toxicity and tolerability will be assessed. self-reporting measures of comorbidity, depression and functional status will be evaluated. Clinical pharmacology of the drugs paclitaxel and gemcitabine in both this age group and those patients under 60 will be assessed. Those under 60 will be compared to patients reported in the literature. The feasibility of exploring genetic polymorphisms will be explored.